Trinity Biotech
TRIB
19 hedge funds and large institutions have $8.92M invested in Trinity Biotech in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 5 closing their positions.
0.04% less ownership
Funds ownership: 0.07% → 0.03% (-0.04%)
7% less capital invested
Capital invested by funds: $9.56M → $8.92M (-$638K)
10% less funds holding
Funds holding: 21 → 19 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
86% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristides Capital
Louisville,
Kentucky
|
+$294K |
| 2 |
Renaissance Technologies
New York
|
+$42.5K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$13.6K |
| 4 |
BlackRock
New York
|
+$1.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$1.22M |
| 2 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
-$737K |
| 3 |
Morgan Stanley
New York
|
-$74.4K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$67.4K |
| 5 |
LPL Financial
San Diego,
California
|
-$64.6K |
TRIB Hedge Fund Activity: Q2 2022 in Review
19 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q2 2022, worth a combined $8.92M — down 6.7% from $9.56M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TRIB and 3 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 1 added.
The largest buyer was Aristides Capital, opening a new position worth an estimated $294K. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $1.22M sold.
- 19 institutional investors held Trinity Biotech (TRIB) as of Q2 2022, down from 21 in Q1 2022.
- Funds reported $8.92M of Trinity Biotech stock for Q2 2022, down 6.7% quarter-over-quarter.
- 3 funds opened new Trinity Biotech positions in Q2 2022 and 5 closed out, a net change of -2 holders.
- The largest Trinity Biotech buyer in Q2 2022 was Aristides Capital, an estimated $294K added.
- The largest Trinity Biotech seller in Q2 2022 was Highbridge Capital Management, an estimated $1.22M sold.
Based on aggregated 13F filings for Q2 2022.